Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to explore the value of new MR technology in assessing the systemic metabolism, disease status, and prognostic risk of metabolism-related fatty liver disease. By obtaining clinical, imaging, laboratory examination and pathological data of metabolism-related fatty liver disease, image processing software is used to analyze the images, explore the relationship between imaging parameters, body composition and metabolic diseases and metabolism-related fatty liver disease, and achieve non-invasive diagnosis, efficacy evaluation, and prognosis prediction of metabolism-related fatty liver disease. Thereby guiding clinical treatment and improving the prognosis and quality of life of patients with metabolism-related fatty liver disease

Who May Be Eligible (Plain English)

Who May Qualify: 1. Patients with MR examination are clinically suspected or diagnosed with metabolism-related fatty liver disease; 2. Age/gender: unlimited; 3. Patients who voluntarily participate in clinical trials and sign written subject willing to sign a consent form Who Should NOT Join This Trial: 1. Clinical suspicion or diagnosis of metabolism-related fatty liver disease and having been prescribed an MR examination; 2. Voluntarily participation in the study and provision of written willing to sign a consent form. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Patients with MR examination are clinically suspected or diagnosed with metabolism-related fatty liver disease; 2. Age/gender: unlimited; 3. Patients who voluntarily participate in clinical trials and sign written subject informed consent Exclusion Criteria: 1. Clinical suspicion or diagnosis of metabolism-related fatty liver disease and having been prescribed an MR examination; 2. Voluntarily participation in the study and provision of written informed consent.

Locations (1)

Tongji hospital
Wuhan, Hubei, China